RGNTNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31

REGENTIS BIOMATERIALS LTD.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Feb 24, 2026

$1.48−0.01 (-0.67%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Earnings

Quarterly results announced on Form 8-K, Item 2.02

No earnings releases found

Regentis Biomaterials has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.

Press releases

Announcements Regentis Biomaterials filed with the SEC

Oct 13, 2026, 6:08 AM ET
PRESS RELEASE DATED OCTOBER 12, 2026
EX-99.1 to Form 6-K
Sep 11, 2026, 9:15 AM ET
PRESS RELEASE DATED SEPTEMBER 11, 2026
EX-99.1 to Form 6-K
Sep 11, 2026, 9:15 AM ET
AS OF AND FOR THE SIX MONTHS ENDED JUNE 30,
EX-99.2 to Form 6-K
Sep 11, 2026, 9:15 AM ET
OPERATING AND FINANCIAL REVIEW AND PROSPECTS AS OF JUNE 30, 2026
EX-99.3 to Form 6-K
Jul 20, 2026, 9:12 AM ET
REGENTIS RECEIVES JAPANESE PATENT ALLOWANCE, STRENGTHENING ITS GLOBAL GELRINC INTELLECTUAL PROPERTY PORTFOLIO WITH NEW PROPRIETARY MANUFACTURING TECHNOLOGY
EX-99.1 to Form 6-K
Jul 15, 2026, 9:15 AM ET
PRESS RELEASE DATED JULY 15, 2026
EX-99.1 to Form 6-K
Jun 18, 2026, 5:26 PM ET
PRESS RELEASE DATED JUNE 17, 2026
EX-99.1 to Form 6-K
Jun 8, 2026, 9:00 AM ET
PRESS RELEASE DATED JUNE 8, 2026
EX-99.1 to Form 6-K
May 28, 2026, 4:45 PM ET
NOTICE AND PROXY STATEMENT WITH RESPECT TO THE COMPANY'S ANNUAL GENERAL MEETING OF SHAREHOLDERS
EX-99.1 to Form 6-K
May 28, 2026, 4:45 PM ET
PROXY CARD FOR HOLDERS OF ORDINARY SHARES WITH RESPECT TO THE COMPANY'S ANNUAL GENERAL MEETING OF SHAREHOLDERS
EX-99.2 to Form 6-K
Feb 24, 2026, 4:20 PM ET
PRESS RELEASE DATED FEBRUARY 24, 2026
EX-99.1 to Form 6-K
Feb 17, 2026, 9:39 AM ET
PRESS RELEASE TITLED: "REGENTIS EXPANDS ITS EUROPEAN CLINICAL SITE NETWORK TO SUPPORT ITS COMMERCIAL AND CLINICAL PROGRAMS."
EX-99.1 to Form 6-K
Feb 5, 2026, 6:43 AM ET
PRESS RELEASE TITLED: "REGENTIS BIOMATERIALS APPOINTS ORI GON AS CHIEF FINANCIAL OFFICER AND CHIEF BUSINESS OFFICER AS GELRINC PROGRESSES TOWARDS COMMERCIAL LAUNCH IN EUROPE AND ADVANCES IN U.S. PHASE III FDA TRIAL."
EX-99.1 to Form 6-K
Jan 29, 2026, 9:09 AM ET
PRESS RELEASE TITLED: "REGENTIS EXPANDING PIVOTAL PHASE III GELRINC CLINICAL SITE NETWORK: ADDING SEVERAL LEADING ORTHOPEDIC CENTERS ACROSS THE U.S."
EX-99.1 to Form 6-K
Jan 20, 2026, 9:07 AM ET
PRESS RELEASE TITLED: "REGENTIS' GELRINC DEMONSTRATES BREAKTHROUGH IN REGENERATING NATIVE-LIKE CARTILAGE STRUCTURE IN KNEE REPAIR ON MRI RESULTS CONFIRMED USING A VALIDATED, REGULATOR-ACCEPTED METHOD"
EX-99.1 to Form 6-K
Jan 6, 2026, 8:51 AM ET
PRESS RELEASE TITLED: "REGENTIS' GELRINC ESTABLISHES LONG-TERM DURABILITY OF CARTILAGE REPAIR THROUGH QUANTITATIVE MOCART EVALUATION"
EX-99.1 to Form 6-K
Dec 18, 2025, 8:48 AM ET
PRESS RELEASE TITLED: "REGENTIS BIOMATERIALS GRANTED NEW U.S. PATENT FOR ITS OFF-THE-SHELF REGENERATIVE CARTILAGE REPAIR PRODUCT GELRINC"
EX-99.1 to Form 6-K
Dec 5, 2025, 4:15 PM ET
PRESS RELEASE TITLED: "REGENTIS BIOMATERIALS LTD. ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING"
EX-99.1 to Form 6-K
Dec 5, 2025, 4:15 PM ET
PRESS RELEASE TITLED: "REGENTIS BIOMATERIALS LTD. ANNOUNCES CLOSING OF INITIAL PUBLIC OFFERING"
EX-99.2 to Form 6-K